Testing

Horatiu Olteanu, M.D., Ph.D., gives an overview of the new T-cell receptor (TCR) β-chain constant region (TRBC1) flow cytometry marker, which is now included in Mayo Clinic Laboratories' routine diagnostic T-cell flow cytometry panel. He discusses when this testing should be ordered, how the addition of TCRBC1 compares to previous testing approaches, and how this marker can assist ordering physicians.

The following list includes updates posted to mayocliniclabs.com during the month of July

In the last decade or so, genetic testing has evolved from single-gene Sanger based assays to much more complex next-generation sequencing (NGS) based assays. This incredible technology has facilitated the rapid and high-throughput evaluation of many genes (hundreds of thousands of DNA strands) all at once.

In June 2020, Mayo Clinic Laboratories announced three new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

View a full list of new CPT codes, Test Classification Updates, LOINC Codes, and Z-Codes posted to mayocliniclabs.com during the month of June.

Mucopolysaccharidosis type I (MPS I) is a rare genetic disorder that typically presents with progressive multisystem involvement in early childhood. This condition results from the deficiency of the enzyme, alpha-L-iduronidase (IDUA), which is responsible for breaking down complex sugars called glycosaminoglycans (GAGs).

In May 2020, Mayo Clinic Laboratories announced three new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

Andre Oliveira, M.D., Ph.D., gives an overview of this testing available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to previous testing approaches, and what clinical action can be taken due to the results of this testing.

View a full list of new CPT codes, Test Classification Updates, LOINC Codes, and Z-Codes posted to mayocliniclabs.com during the month of May.

Sarcomas are malignant tumors that arise in the bone and soft tissue. With numerous subtypes of sarcoma that can have overlapping histological, immunophenotypic, and clinical features, diagnosis can be extremely challenging

Mayo Clinic’s Biochemical Genetics Laboratory has announced an updated second-tier test to detect Krabbe disease (KD) that uses psychosine (PSY) as a disease marker. The new test method has significantly higher sensitivity to detect this devastating disease in infants and allows identification of KD patients with minimal psychosine elevations.

In April 2020, Mayo Clinic Laboratories announced four new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

Immunotherapies have recently emerged as a therapeutic option for patients with non-small-cell lung carcinoma (NSCLC). Therapies have been approved for both first and second-line treatments[...]